Massachusetts Financial Services Co. MA Purchases Shares of 14,419 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Massachusetts Financial Services Co. MA acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 14,419 shares of the company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock valued at $149,413,000 after purchasing an additional 14,960 shares during the period. Pacer Advisors Inc. raised its stake in Pacira BioSciences by 37.5% during the 2nd quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock worth $61,877,000 after buying an additional 590,082 shares during the period. Renaissance Technologies LLC boosted its holdings in Pacira BioSciences by 9.8% in the second quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock worth $59,114,000 after acquiring an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Pacira BioSciences by 12.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after acquiring an additional 198,936 shares during the period. Finally, Doma Perpetual Capital Management LLC increased its holdings in shares of Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after acquiring an additional 418,321 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Royal Bank of Canada increased their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. HC Wainwright lowered their target price on shares of Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Jefferies Financial Group lifted their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Finally, Truist Financial downgraded Pacira BioSciences from a “buy” rating to a “sell” rating and cut their target price for the stock from $30.00 to $8.00 in a research note on Tuesday, August 13th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $23.50.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $16.64 on Thursday. The stock has a market cap of $768.27 million, a price-to-earnings ratio of -8.20 and a beta of 0.82. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a 50-day simple moving average of $16.37 and a 200 day simple moving average of $20.03. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $35.95.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.